RegeneRx Biopharmaceuticals, Inc. (NYSE Amex:RGN) ("the Company" or "RegeneRx") announced that the Company received a patent in Australia using thymosin beta 4 (Tβ4), and various fragments and anologues of Tβ4, to treat or prevent biological and immunological responses to reactive chemical, biological or toxic agents.
The patent claims include allergic reactions such as contact dermatitis, poison ivy, and insect bites, as well as skin indications such as psoriasis and eczema, among others. The patent expires in 2024. RegeneRx has patents pending for this use in a number of countries, including the U.S.